Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.
Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
ATHX's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions.
Athersys has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb to provide cell lines expressing well validated drug targets for compound screening and development.
Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
March 15, 2022
RegMed Investors’ (RMi) closing bell: it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation
March 15, 2022
RegMed Investors’ (RMi) pre-open: cell and gene therapy sector, not lookin’ good
March 14, 2022
RegMed Investors’ (RMi) closing bell: just when I thought sentiment would rebound and lift the cell and gene therapy sector
March 14, 2022
RegMed Investors’ (RMi) pre-open: the phoenix rises from the shares as do share pricings after being burned to a crisp
March 11, 2022
RegMed Investors’ (RMi) closing bell: escalated depreciation in the cell and gene therapy sector
March 11, 2022
RegMed Investors’ (RMi) pre-open: dramatic market and sector moves are still questionable
March 10, 2022
RegMed Investors’ (RMi) closing bell: the algorithms beat me to the profit window
March 10, 2022
RegMed Investors’ (RMi) pre-open: time to take some chips off the table
March 9, 2022
RegMed Investors’ (RMi) closing bell: a pocket of appreciation, how long will it last?
March 9, 2022
RegMed Investors’ (RMi) pre-open: tread lightly, add, trim or hedge as needed
35 companies, 1 interpreter!
Insight, foresight and recommendation
Athersys (ATHX) – Started 1/18 at $1.81, dropping on 2/1 to $1.76 and was trading at $1.44 on 2/16 ... after initiating a follow-on equity facility to a current facility. Under the new agreement, ATHX has the right to sell up to $100 million of its common stock to Aspire Capital under certain conditions over a three-year period. In conjunction with the new facility, Aspire made an initial investment of $1 million at a price of $2.00 per share. As of 12/31/17t, ATHX had approximately $29.3 million of cash and cash equivalents available to fund operations. DON’T look for follow through appreciation as the stock based debt facility will be selling shares into ANY strength …
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors